List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. IGF OT IGF TREATMENT OF TUBERCULOSIS WITH INHALED DELIVERY OF CLOFAZIMINE

    SBC: AEROPHASE INC            Topic: NIAID

    Not Available

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. IGF OT IGF TITLE CHEMO ENZYMATIC SYNTHESIS OF STRUCTURALLY DEFINED COMPLEX TYPE N GLYCANS

    SBC: CHEMILY, LLC            Topic: NCI

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. IGF OT IGF SMOKESCREEN GENETIC SCREENING TOOL FOR TOBACCO DEPENDENCE and TREATMENT APPROACHES POP MOD SUPPLEMENT WITHIN SCOPE AND EXTENSION

    SBC: BioRealm LLC            Topic: NIDA

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. IGF OT IGF CONTRACT TITLE RADIATION MODULATORS FOR HEAD AND NECK CANCERPOP

    SBC: SuviCa, Inc.            Topic: NCI

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Smartphone Technology for Parents and Teens: Improving Vaccination Uptake

    SBC: KLEIN BUENDEL, INC            Topic: NICHD

    DESCRIPTION provided by applicant Vaccinations for adolescents in the U S tetanus diphtheria and acellular pertussis Tdap meningococcal conjugate vaccine MCV Human Papillomavirus HPV vaccines Gardasil and Cervarex remain well below the Centers for Disease Control and Prevention CDC goals and especially so for the HPV vaccines These vaccine deficits are pronounced among minor ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Isotopically Labeled Glycoproteins for use as Internal Standards

    SBC: GlycoScientific, L.L.C.            Topic: 300

    DESCRIPTION provided by applicant The ability to accurately quantitate the glycan chains attached to glycoproteins has wide ranging implications Numerous studies over the past years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers and demonstrate the potential of using glycan markers in either a diagnostic or a prognostic manner The glycosylatio ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation

    SBC: Cambium Medical Technologies LLC            Topic: N

    DESCRIPTION provided by applicant Ocular graft versus host disease O GVHD is a particularly severe and debilitating complication of allogeneic hematopoietic stem cell transplantation HSCT O GVHD develops in of patients with chronic GVHD Currently Restasis cyclosporine A is the only FDA approved prescription topical medication to treat O GVHD In Restasis had sales o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Anti-CXCL13 mAb to mitigate prostate cancer health disparities

    SBC: JYANT Technologies, Inc.            Topic: NIMHD

    DESCRIPTION provided by applicant The most common metastatic site for hormone refractory prostate cancer HRPC PCa is bone While docetaxel can prolong the overall survival in patients with metastatic HRPC current treatments do not provide a cure Further complicating the matter HRPC is a disease that affects a variety of patients differently which can be problematic for physicians to prov ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Diagnosis of Bacterial Infections with Maltodexrins

    SBC: Microbial Medical, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant We present a new family of contrast agents based on targeting the maltodextrin transporter termed maltodextrin based imaging probes MDPs which are designed to image infections associated with implanted medical devices by fluorescent imaging The chemical structure of an MDP is composed of maltodextrins conjugated to a fluorescent dye MDPs have the potentia ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Humanization of VLR antibodies for therapeutic applications

    SBC: Novab, Inc.            Topic: 102

    DESCRIPTION provided by applicant Currently there is no FDA approved therapeutic antibody capable of depleting long lived plasma cells A plasma cell specific monoclonal antibody could be used to treat plasma cell malignancies multiple myelomas which are fatal and for which there is no effective treatment and antibody mediated autoimmune and severe allergic disease e g systemic lupus e ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government